Baidu
map
ALLERGY ASTHMA PROC 润色咨询

ALLERGY AND ASTHMA PROCEEDINGS

出版年份:1996 年文章数:968 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:14.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    RUNINGTITLE是必须的么?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2021-12-27 桑晒麦拉

    RUNNINGTITLE和TITLE的区别?

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2018-04-09 树梢上的皓月

    "Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2018-04-09 树梢上的皓月

    "Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2018-02-03 ms2877410299030514

    主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2018-02-03 G-01f74241

    审稿速度:3.0 | 投稿命中率:75.0
    经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2017-11-28 二川溶溶

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:2016年为
    2.614
    2015年为
    2.709
    2014年为
    3.061

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1086373, encodeId=b70410863e36c, content=RUNINGTITLE是必须的么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086374, encodeId=ee1a10863e4f9, content=RUNNINGTITLE和TITLE的区别?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554728, encodeId=2464554e28f1, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=268, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:45:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=554727, encodeId=81a1554e2707, content="Allergy and Asthma Proceedings does not accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office" 这是什么意思,只接受约稿?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b071660285, createdName=树梢上的皓月, createdTime=Mon Apr 09 18:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=840849, encodeId=6db5840849fe, content=主编和责任编辑非常好沟通,2位同行评审给出的意见诚恳并有助于进一步完善内容。返修不会给时间限制,个人控制在10天左右,返修后编辑回复很快。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df505414113, createdName=ms2877410299030514, createdTime=Sat Feb 03 14:29:17 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552308, encodeId=1bd25523089d, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:2017年底上传了一份过敏性疾病的meta分析手稿,经过3个月返回第一轮修改意见,2位同行评审,提出意见不多属于可接受范围,没有修稿时间限制,个人控制在10天之内;之后只需要修改一个句子的表达以及调整图片,10+天得到最终的Decision Letter。虽然过程紧张,但主编和责任编辑都非常好沟通!小白第一次亲自投稿被接收有点小激动。祝大家顺利~希望有帮助。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=317, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c871711639, createdName=G-01f74241, createdTime=Sat Feb 03 14:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549558, encodeId=08a65495583a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:2016年为 <br> 2.614 <br> 2015年为 <br> 2.709 <br> 2014年为 <br> 3.061 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=293, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e7bb1996859, createdName=二川溶溶, createdTime=Tue Nov 28 18:40:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=832739, encodeId=eb44832e39bc, content=可以,感觉不错。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=573a5414124, createdName=ms622773450447966, createdTime=Mon Jul 11 16:25:05 CST 2016, time=2016-07-11, status=1, ipAttribution=)]
    2016-07-11 ms622773450447966

    可以,感觉不错。

    0

共10条页码: 1/1页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map